Status:
UNKNOWN
Resectability of Pancreatic Head Cancer by Contrast-enhanced MDCT:a Multi-center Study
Lead Sponsor:
Meng Su Zeng
Collaborating Sponsors:
Changhai Hospital
Shanghai Cancer Hospital, China
Conditions:
Adenocarcinoma of Head of Pancreas
Eligibility:
All Genders
Brief Summary
The purpose of this multicenter and double-blind clinical trial is to prospectively assess the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy in respectab...
Eligibility Criteria
Inclusion
- Patients with (or suspected) pancreatic head cancer
- Being examined by contrasted-enhanced MDCT
- Receiving surgical treatment (including palliative surgery) in all research centers
Exclusion
- Patients having (or suspected) pregnancy or breast-feeding
- Patients having allergic reactions to iodinated contrast agents or Hypersensitivity reactions to allergens(including drugs)
- Patients receiving ERCP before contrasted-enhanced MDCT examination
- Patients without surgery because of a high degree of surgical risk
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2012
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT01455610
Start Date
October 1 2011
End Date
October 1 2012
Last Update
October 20 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Radiology Department, Ruijing Hospital, Shanghai Jiaotong University
Shanghai, Shanghai Municipality, China, 200025
2
Radiology Department, Cancer Hospital, Fuandan University
Shanghai, Shanghai Municipality, China, 200032
3
Radiology Department, Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032
4
Radiology Department, Huadong Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200040